So low ... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

被引：35
|
作者：
Gencer, Baris [1 ]
Mach, Francois [1 ]
机构：
[1] Geneva Univ Hosp, Dept Specialties Med, Cardiol Div, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
COGNITIVE FUNCTION; FOURIER TRIAL; OLDER-ADULTS; CHOLESTEROL; EFFICACY; SAFETY; METAANALYSIS; EVOLOCUMAB; STATINS; DISEASE;
D O I：
10.1093/eurheartj/ehx742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: meta-analysis of individual patient data'+, by P.D. Harvey et al., on page 374.
引用
收藏
页码：382 / 384
页数：3
相关论文
共 50 条
  • [21] Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
    Drummond, MW
    Holyoake, TL
    BLOOD REVIEWS, 2001, 15 (02) : 85 - 95
  • [22] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
  • [23] PCSK9 and LDL-C Lowering Effect of SOAP Targeting siRNA in Mouse and Non-Human Primate Models
    Jensen, Kristian K.
    Tadin-Strapps, Marija
    Wang, Sheng-Ping
    Herath, Kithsiri
    Hubert, James
    Kan, Yanqing
    Rosa, Ray
    Szeto, Daphne
    Williams, Stephanie
    Xie, Dan
    Zhou, Haihong
    Forrest, Gail
    Previs, Stephen F.
    McLaren, David G.
    Sepp-Lorenzino, Laura
    Pinto, Shirly
    CIRCULATION, 2014, 130
  • [24] EVOLOCUMAB PHARMACOKINETICS AND ITS EFFECTS ON LDL-C AND PCSK9 LOWERING IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT.
    Emery, M. G.
    Gibbs, J. P.
    Slatter, J. G.
    Hamilton, L.
    Wasserman, S. M.
    Geller, M.
    Dias, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S69 - S69
  • [25] Is treating severe He FH so easy? A combined treatment between lipoprotein apheresis and PCSK9 inhibitors
    Dal Pino, Beatrice
    Sbrana, Francesco
    Bigazzi, Federico
    Sampietro, Tiziana
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (06)
  • [26] PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
    Keith C. Ferdinand
    Samar A. Nasser
    Cardiovascular Drugs and Therapy, 2015, 29 : 295 - 308
  • [27] PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
    Ferdinand, Keith C.
    Nasser, Samar A.
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (03) : 295 - 308
  • [28] Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice
    Gu, Lili
    Gong, Yaqin
    Zhao, Cheng
    Wang, Yue
    Tian, Qinghua
    Lei, Gaoxin
    Liang, Yalin
    Zhao, Wenfeng
    Tan, Shuhua
    MOLECULES, 2019, 24 (22):
  • [29] THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB)
    Skove, Stephanie
    Anderson, Jeffrey L.
    Le, Viet T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2474 - 2474
  • [30] 'LDL-C' = LDL-C plus Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering
    Yeang, Calvin
    Witztum, Joseph L.
    Tsimikas, Sotirios
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (03) : 169 - 178
12345